cytena Bioprocess Solutions co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50899774
Status
Active
Number of Employees
0
Total Paid-in
Capital
29,051,130 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Acquired(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting.
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.
The content above was translated by Ai
